A
Anna Karolina Palucka
Publications - 5
Citations - 1285
Anna Karolina Palucka is an academic researcher. The author has contributed to research in topics: T cell & Melanoma. The author has an hindex of 3, co-authored 5 publications receiving 968 citations.
Papers
More filters
Journal ArticleDOI
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon,Juliana Idoyaga,Adeeb Rahman,Marylene Leboeuf,Romain Remark,Stefan Jordan,Maria Casanova-Acebes,Makhzuna Khudoynazarova,Judith Agudo,Navpreet Tung,Svetoslav Chakarov,Christina Rivera,Brandon Hogstad,Marcus Bosenberg,Daigo Hashimoto,Sacha Gnjatic,Nina Bhardwaj,Anna Karolina Palucka,Brian D. Brown,Joshua Brody,Florent Ginhoux,Miriam Merad +21 more
TL;DR: The paucity of activated CD103(+) DCs in tumors limits checkpoint-blockade efficacy and combined FLT3L and poly I:C therapy can enhance tumor responses to checkpoint and BRAF blockade.
Journal ArticleDOI
Classification of current anticancer immunotherapies
Lorenzo Galluzzi,Erika Vacchelli,José Manuel Bravo-San Pedro,Aitziber Buqué,Laura Senovilla,Elisa E. Baracco,Norma Bloy,Francesca Castoldi,Jean Pierre Abastado,Patrizia Agostinis,Ron N. Apte,Fernando Aranda,Maha Ayyoub,Philipp Beckhove,Jean-Yves Blay,Laura Bracci,Anne Caignard,Chiara Castelli,Federica Cavallo,Estaban Celis,Vincenzo Cerundolo,Aled Clayton,Mario P. Colombo,Lisa M. Coussens,Madhav V. Dhodapkar,Alexander M.M. Eggermont,Douglas T. Fearon,Wolf H. Fridman,Jitka Fucikova,Dmitry I. Gabrilovich,Jérôme Galon,Abhishek D. Garg,François Ghiringhelli,François Ghiringhelli,Giuseppe Giaccone,Giuseppe Giaccone,Eli Gilboa,Sacha Gnjatic,Axel Hoos,Anne Hosmalin,Anne Hosmalin,Anne Hosmalin,Dirk Jäger,Pawel Kalinski,Klas Kärre,Oliver Kepp,Rolf Kiessling,John M. Kirkwood,Eva Klein,Alexander Knuth,Claire E. Lewis,Roland S. Liblau,Roland S. Liblau,Roland S. Liblau,Michael T. Lotze,Enrico Lugli,Jean-Pierre Mach,Fabrizio Mattei,Domenico Mavilio,Ignacio Melero,Cornelis J. M. Melief,E. A. Mittendorf,Lorenzo Moretta,Adekunke Odunsi,Hideho Okada,Anna Karolina Palucka,Marcus E. Peter,Kenneth J. Pienta,Angel Porgador,George C. Prendergast,George C. Prendergast,Gabriel A. Rabinovich,Nicholas P. Restifo,Naiyer A. Rizvi,Catherine Sautès-Fridman,Hans Schreiber,Barbara Seliger,Hiroshi Shiku,Bruno Silva-Santos,Mark J. Smyth,Mark J. Smyth,Daniel E. Speiser,Daniel E. Speiser,Radek Spisek,Pramod K. Srivastava,James E. Talmadge,Eric Tartour,Sjoerd H. van der Burg,Benoît Van den Eynde,Benoît Van den Eynde,Richard G. Vile,Hermann Wagner,Jeffrey S. Weber,Theresa L. Whiteside,Jedd D. Wolchok,Jedd D. Wolchok,Laurence Zitvogel,Weiping Zou,Guido Kroemer +98 more
TL;DR: A critical, integrated classification of anticancer immunotherapies is proposed and the clinical relevance of these approaches is discussed.
Journal ArticleDOI
Consensus nomenclature for CD8+ T cell phenotypes in cancer
Lionel Apetoh,Mark J. Smyth,Charles G. Drake,Jean Pierre Abastado,Ron N. Apte,Maha Ayyoub,Jean-Yves Blay,Marc Bonneville,Lisa H. Butterfield,Anne Caignard,Chiara Castelli,Federica Cavallo,Esteban Celis,Lieping Chen,Mario P. Colombo,Begoña Comin-Anduix,G. Coukos,Madhav V. Dhodapkar,Glenn Dranoff,Ian H. Frazer,Wolf Hervé Fridman,Dmitry I. Gabrilovich,Eli Gilboa,Sacha Gnjatic,Dirk Jäger,Pawel Kalinski,Howard L. Kaufman,Rolf Kiessling,John M. Kirkwood,Alexander Knuth,Roland S. Liblau,Michael T. Lotze,Enrico Lugli,Francesco M. Marincola,Ignacio Melero,Cornelis J. M. Melief,Thorsten R. Mempel,Elizabeth A. Mittendorf,Kunle Odun,Willem W. Overwijk,Anna Karolina Palucka,Giorgio Parmiani,Antoni Ribas,Pedro Romero,Robert D. Schreiber,Gerold Schuler,Pramod K. Srivastava,Eric Tartour,Danila Valmori,Danila Valmori,Sjoerd H. van der Burg,Pierre van der Bruggen,Benoît Van den Eynde,Ena Wang,Weiping Zou,Theresa L. Whiteside,Daniel E. Speiser,Drew M. Pardoll,Nicholas P. Restifo,Ana C. Anderson +59 more
TL;DR: The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8- T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor".
Proceedings ArticleDOI
Abstract B015: Expansion and activation of CD103+dendritic cell progenitors at the tumor site transform tumor response to PD-L1 and BRAF inhibition
Hélène Salmon,Juliana Idoyaga,Adeeb Rahman,Romain Remark,Sacha Gnjatic,Nina Bhardwaj,Joshua Brody,Anna Karolina Palucka,Florent Ginhoux,Miriam Merad +9 more
TL;DR: Modulation of intratumoral antigen presenting cells (APCs) can help increase response to BRAF and checkpoint blockade in tamoxifen-induced Braf -mutant and B16 melanoma lesions and Flt3L-poly I:C therapy can transform clinical responses to checkpoint and BRAF blockade.
Proceedings ArticleDOI
Abstract B058: Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell accumulation in melanoma lesions and transform clinical response to BRAF and PD-L1 blockade
Hélène Salmon,Juliana Idoyaga,Adeeb Rahman,Anna Karolina Palucka,Nina Bhardwaj,Florent Ginhoux,Miriam Merad +6 more
TL;DR: The paucity of activated CD103+ DC in tumors limit checkpoint blockade efficacy and Flt3L/poly I:C combination can significantly enhance clinical response to checkpoint and BRAF blockade.